WEBULL
WebtradeDownload

Incyte (INCY) Stock Could Be 30% Overvalued As MINJUVI Funding Lands

Simply Wall St · 2d ago

Incyte has more than doubled investors' money over the past three years, so the obvious question now is whether that kind of share price outcome lines up with the cash the business is expected to generate. With the stock recently closing at US$121.74, the focus turns to what the current market tag implies for the long term cash flows that underpin Incyte's value.

  • Incyte has delivered a 100.9% return over three years, which puts real weight on the question of whether recent share price strength is fully supported by its future cash generation.
  • Funding access for MINJUVI in Ontario through the FAST Program may support expectations for future oncology revenue and influence how investors think about the timing and durability of Incyte's cash flows.
  • If you'd rather focus on earnings, this one's for you. See why Incyte's 15.3x P/E tells a different valuation story.

The issue now is whether the current share price can be explained by what the Discounted Cash Flow (DCF) view of Incyte's future cash flows suggests the business is worth.

You can apply the same cash flow lens you are using for Incyte across a wider field of potential ideas by scanning companies in the 34 high quality undervalued stocks

Is Incyte Getting Expensive on Cash Flow?

The Discounted Cash Flow model looks at the cash Incyte is expected to generate for shareholders and then adjusts those future dollars back to today. On this view, the latest twelve month free cash flow sits at about $1.89b, while analyst projections in the model point to lower free cash flow levels in later years, so the cash profile is treated as declining rather than growing.

Because the DCF projections put Incyte's estimated intrinsic value substantially below the current share price of US$121.74, the market is assigning a richer tag to the stock than these cash flow assumptions would support. Funding access for MINJUVI in Ontario through the FAST Program may help sentiment around longer term oncology cash flows. However, the current valuation still looks ahead of what this particular DCF framework implies. You can see how all of those moving parts come together in the full calculation. Find out what Incyte could be worth using our Discounted Cash Flow (DCF) estimate.

The Incyte Narrative: What Would Justify Today's Price?

Narratives pick up where the DCF puzzle leaves off. They explain which assumptions about Incyte's future growth, margins and earnings would need to hold for the stock to be worth meaningfully more or less than it is today. Each narrative links a specific fair value to a clear storyline about Incyte's potential catalysts and risks, so you can track over time which version of events is actually unfolding on the Community page.

The community is split on Incyte, with one camp seeing more long term optionality than the other at roughly similar headline valuations.

Bull case: roughly fairly valued

"Strengthened and diversified product portfolio momentum (with Jakafi, Opzelura, Niktimvo, Monjuvi, and Zynyz all delivering robust growth) alongside an active business development pipeline increases resilience against biosimilar/generic threats..."

Discover why this Narrative puts Incyte at roughly fairly valued.

Bear case: 31% overvalued

"The company's heavy reliance on Jakafi exposes it to severe concentration risk, with biosimilar competition and patent expiry after 2028 expected to cause a sharp decline in sales and profitability..."

Explore why this Narrative puts Incyte at 31% overvalued.

Before acting on Incyte's valuation, there is one more influence to consider

Price targets and cash flow models only go so far if the people steering Incyte are rewarded in ways that pull their priorities away from yours. See who runs Incyte and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.